The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

European Journal of Surgical Oncology

Volumn 36, Issue 4, 2010, Pages 387-392

  Aukema, T S ^a   Rutgers, E J Th ^a   Vogel, W V ^a   Teertstra, H J ^a   Oldenburg, H S ^a   Vrancken Peeters, M T F D ^a   Wesseling, J ^a   Russell, N S ^a   Valdes Olmos R A ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Neoplasm staging; Patient management; Positron emission tomography; Recurrence; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; DIAGNOSTIC ACCURACY; DISTANT METASTASIS; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; WHOLE BODY CT; WHOLE BODY PET;

ADULT; AGED; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 77949266477     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2009.11.009     Document Type: Article

References (29)

1. Voogd A.C., Nielsen M., Peterse J.L., et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 19 6 (2001) 1688-1697
2. Van Tienhoven G., Voogd A.C., Peterse J.L., et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC breast cancer cooperative group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 35 1 (1999) 32-38
3. Aukema T.S., Russell N.S., Wesseling J., and Rutgers E.J. Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity. Eur J Surg Oncol 35 5 (2009) 469-474
4. van Oost F.J., van der Hoeven J.J., Hoekstra O.S., Voogd A.C., Coebergh J.W., and van de Poll-Franse L.V. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer 40 10 (2004) 1545-1553
5. Voogd A.C., van Tienhoven G., Peterse H.L., et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch study group on local recurrence after breast conservation (BORST). Cancer 85 2 (1999) 437-446
6. Haffty B.G., Fischer D., Beinfield M., and McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys 21 2 (1991) 293-298
7. Halverson K.J., Perez C.A., Kuske R.R., Garcia D.M., Simpson J.R., and Fineberg B. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys 23 2 (1992) 285-291
8. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38 5 (2003) 250-256
9. Grahek D., Montravers F., Kerrou K., Aide N., Lotz J.P., and Talbot J.N. [18F]-FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging 31 2 (2004) 179-188
10. Isasi C.R., Moadel R.M., and Blaufox M.D. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90 2 (2005) 105-112
11. Kamel E.M., Wyss M.T., Fehr M.K., von Schulthess G.K., and Goerres G.W. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol 129 3 (2003) 147-153
12. Pelosi E., Messa C., Sironi S., et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imag 31 7 (2004) 932-939
13. Antoch G., Saoudi N., Kuehl H., et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22 21 (2004) 4357-4368
14. Abner A.L., Recht A., Eberlein T., et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 11 1 (1993) 44-48
15. Clark G.M., Sledge Jr. G.W., Osborne C.K., and McGuire W.L. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5 1 (1987) 55-61
16. Dose J., Bleckmann C., Bachmann S., et al. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients. Nucl Med Commun 23 9 (2002) 857-864
17. Mahner S., Schirrmacher S., Brenner W., et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol 19 7 (2008) 1249-1254
18. Schirrmeister H., Kuhn T., Guhlmann A., Santjohanser C., Horster T., Nussle K., et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 28 3 (2001) 351-358
19. Radan L., Ben Haim S., Bar-Shalom R., Guralnik L., and Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer 107 11 (2006) 2545-2551
20. Suarez M., Perez-Castejon M.J., Jimenez A., et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med 46 2 (2002) 113-121
21. Pivot X., Asmar L., Hortobagyi G.N., Theriault R., Pastorini F., and Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology 58 3 (2000) 185-190
22. Viadana E., Cotter R., Pickren J.W., and Bross I.D. An autopsy study of metastatic sites of breast cancer. Cancer Res 33 1 (1973) 179-181
23. Cook G.J., Houston S., Rubens R., Maisey M.N., and Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16 10 (1998) 3375-3379
24. Langsteger W., Heinisch M., and Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 36 1 (2006) 73-92
25. Lonneux M., Borbath I., Berliere M., Kirkove C., and Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 3 2 (2000) 45-49
26. Yang S.N., Liang J.A., Lin F.J., Kao C.H., Lin C.C., and Lee C.C. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol 128 6 (2002) 325-328
27. 18F]-fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26 29 (2008) 4746-4751
28. Veronesi U., De Cicco C., Galimberti V.E., et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18 3 (2007) 473-478
29. Aukema T.S., Straver M.E., Valdes Olmos R.A., and Vogel W.V. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imag 36 11 (2009) 1896-1897